Seizures clinical trials at UC Irvine

2 research studies open to eligible people

Showing trials for

  • XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    open to eligible people ages 18 years and up

    The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

    Orange, California and other locations

  • XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    open to eligible people ages 12 years and up

    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

    Orange, California and other locations

Last updated: